Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of Galicaftor, Navocaftor and ABBV-576 and Potential of ABBV-576 for CYP3A Induction in Healthy Volunteers
Latest Information Update: 24 Feb 2023
At a glance
- Drugs ABBV 576 (Primary) ; Galicaftor (Primary) ; Midazolam (Primary) ; Navocaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ABBV-576 DDI
- Sponsors AbbVie
Most Recent Events
- 16 Feb 2023 Status changed from recruiting to completed.
- 23 Sep 2022 Status changed from not yet recruiting to recruiting.
- 12 Sep 2022 ABBV-576 DDI indexed as acronym. Please update further.